No Current Vyvanse Recall
There is no evidence of a Vyvanse (lisdexamfetamine dimesylate) recall in the provided medical literature or FDA drug labeling information. The evidence includes current FDA prescribing information from 2026 and recent clinical guidelines from 2024, none of which mention any recall or withdrawal of this medication 1.
Current Status of Vyvanse
Vyvanse remains an FDA-approved medication available in multiple formulations:
- Capsules: 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg 1
- Chewable tablets: 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, and 60 mg 1
The medication continues to be recommended in current clinical practice guidelines for ADHD treatment, with 2024 guidelines from the American Journal of Obstetrics and Gynecology including it as a standard treatment option 2.
Active Clinical Use
Recent evidence confirms ongoing clinical use:
- A 2026 post-marketing surveillance study in Japan involving 1,819 pediatric patients demonstrates active monitoring and use of the medication 3
- Current 2024 guidelines provide detailed dosing recommendations (starting dose 20-30 mg daily, titrating by 10 mg weekly to maximum 70 mg daily) 2
- The medication maintains its controlled substance classification with appropriate distribution controls 4
Important Context
While there is no recall, clinicians should be aware that:
- Vyvanse is a Schedule II controlled substance requiring strict distribution monitoring 1
- The FDA label includes standard warnings about abuse potential, cardiovascular risks, and psychiatric adverse effects 1
- Post-marketing surveillance continues to monitor safety in real-world use 3
If you have concerns about a specific lot or batch, contact the FDA MedWatch program or the manufacturer directly for the most current recall information, as this would be announced through official FDA channels rather than medical literature.